Table 1 Characteristics of the study subjects

Age (years)

60 (50–66)

Gender (% men)

51.3

BMI (Kg/m²)

30.0 (26.9–35.0)

SBP(mmHg)

135 (125–149)

DBP (mmHg)

80 (72–86)

AD (%)

32.1

MetS (%)

78.1

Obesity (%)

50.6

T2DM (%)

72.0

Cholesterol (mmol/L)

5.20 (4.54–6.19)

Triglycerides (mmol/L)

1.54 (0.99–2.45)

LDL-C (mmol/L)

3.27 (2.55–4.07)

HDL-C (mmol/L)

1.40 (1.21–1.62)

Glucose (mg/dL)

128.5 (101.3–164.9)

Apo B100 (mg/dL)

101.0 (84.0–120.0)

Apo A1 (mg/dL)

137.9 ± 14.9

CETP activity (nmol/L per h)

11.6 (10.2–13.3)

LCAT activity (470/390 nm)

2.14 (2.07–2.24)

PCSK9 (ng/mL)

319.9 (254.4–403.9)

PCSK9 rs11591147 GG

94.8

Genotype^a, (%) GT

5.2

Lp particle number

 VLDL (nmol/L)

49.7 (28.5–97.8)

  Large VLDL (nmol/L)

1.83 (1.01–2.99)

  Medium VLDL (nmol/L)

7.87 (4.52–13.6)

  Small VLDL (nmol/L)

39.9 (22.7–82.2)

 LDL (nmol/L)

892.3 (681.8–1175.8)

  Large LDL (nmol/L)

113.4 (87.0–149.4)

  Medium LDL (nmol/L)

319.4 (234.3–417.2)

  Small LDL (nmol/L)

463.5 (337.9–618.5)

 HDL (µL/L)

25.3 (21.6–29.4)

  Large HDL (µL/L)

0.15 (0.11–0.19)

  Medium HDL (µL/L)

6.94 (5.08–9.21)

  Small HDL (µL/L)

17.9 (15.5–20.9)

Lp size (diameter, nm)

 VLDL

42.6 ± 0.57

 LDL

21.0 (20.9–21.1)

 HDL

8.19 (8.12–8.24)